Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure

Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease

(2020) David J. Gibson et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

An in vitro comparison of four different immunoassays for the monitoring of Infliximab biosimilars drug levels

(2020) Benjamin Neveu et al.   CLINICAL BIOCHEMISTRY

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview

(2019) Lieven Pouillon et al.   BMC Medicine

Modulation of cytokine patterns and microbiome during pregnancy in IBD

(2019) Janine van der Giessen et al.   GUT

Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease

(2018) M. Julsgaard et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines

(2018) Dawn B. Beaulieu et al.   Clinical Gastroenterology and Hepatology

Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis

(2018) Sophie E. Berends et al.   CLINICAL PHARMACOKINETICS

Anti-TNF Levels in Cord Blood at Birth are Associated with Anti-TNF Type

(2018) Shannon L Kanis et al.   Journal of Crohns & Colitis

Letter: vedolizumab drug concentrations in neonates following intrauterine exposure

(2018) Emma Flanagan et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease

(2017) Uma Mahadevan et al.   GASTROENTEROLOGY

The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease

(2017) Heidi Kammerlander et al.   INFLAMMATORY BOWEL DISEASES

Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease

(2016) Karin Malíčková et al.   BIOLOGICALS

437 Do Infant Serum Levels of Biologic Agents at Birth Correlate With Risk of Adverse Outcomes? Results From the PIANO Registry

(2016) Uma Mahadevan et al.   GASTROENTEROLOGY

Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection

(2016) Mette Julsgaard et al.   GASTROENTEROLOGY

Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis

(2016) Zaid Shihab et al.   Journal of Crohns & Colitis

Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment

(2014) M. R. K. L. Lie et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES